INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT03837509. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab SC, compared with daratumumab SC alone, in participants with relapsed or refractory multiple myeloma.
Study identification
- NCT ID
- NCT03837509
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 15 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 24, 2019
- Primary completion
- Apr 4, 2022
- Completion
- Apr 4, 2022
- Last update posted
- Nov 3, 2025
2019 – 2022
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Southern Cancer Center | Daphne | Alabama | 36526 | — |
| Arizona Oncology Associates (Wilmot) | Tucson | Arizona | 85711 | — |
| Rocky Mountain Cancer Centers | Denver | Colorado | 80218 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Comprehensive Cancer Centers of Nevada - Twain | Las Vegas | Nevada | 89169 | — |
| New York Oncology Hematology | Albany | New York | 12206 | — |
| Lineberger Comprehensive Cancer Center At University of North Carolina Chapel Hill | Chapel Hill | North Carolina | 27514 | — |
| Oncology Hematology Care, Inc | Cincinnati | Ohio | 45236 | — |
| Texas Oncology-Austin Midtown | Austin | Texas | 78705 | — |
| Texas Oncology - Fort Worth South Henderson | Fort Worth | Texas | 76104 | — |
| Texas Oncology San Antonio | San Antonio | Texas | 78240 | — |
| Texas Oncology - Tyler | Tyler | Texas | 75702 | — |
| University of Virginia | Charlottesville | Virginia | 22903 | — |
| Virginia Cancer Specialists-Fairfax | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03837509, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 3, 2025 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03837509 live on ClinicalTrials.gov.